Lung Cancer: 854 Real Stories

854 stories match lung cancer. 428 of them mention chemotherapy.

Cancer Stories

Ashley, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ROS1 Non-Small Cell Lung Cancer: Ashley's Survivor Story

Patient Info: Ashley, Female, Under 40 | Stage IV

Biomarkers: ROS1-rearranged

Metastatic Site: spine/bone

As of December 2024, Ashley described herself as having no evidence of active disease while continuing nightly ROS1-targeted therapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV lung adenocarcinoma: clinical complete remission with pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: No EGFR/ALK/BRAF driver alteration; PD-L1 <1%; high TMB in tissue and blood; immune-cell markers reported.

Metastatic Site: bilateral lungs, mediastinal lymph nodes, right hilar…

Clinical complete remission by RECIST while receiving pembrolizumab monotherapy for driver-negative, PD-L1-negative, high-TMB Stage IV lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
Natalie, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Natalie's Patient Story

Patient Info: Natalie, Female | Stage IV

Metastatic Site: lungs, lymph nodes

As of December 2024, Natalie had restarted chemotherapy after progression, and the current chemotherapy had stopped growth for the moment while she continued transplant evaluation.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Metastatic EGFR-positive lung adenocarcinoma: osimertinib cardiomyopathy managed with SGLT2 inhibitor support

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-positive; specific EGFR sequence variant not reported in extracted case text

As of December 2024, he remained clinically stable and asymptomatic 12 months after osimertinib rechallenge with empagliflozin, losartan, metoprolol, and close cardiac monitoring; the extracted case focuses on cardiotoxicity management rather than tumor response.

PubMed Central
OutcomeCare Ongoing
Amanda, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Amanda's Patient Story

Patient Info: Amanda, Female, Under 40 | Stage IV

Biomarkers: ALK-rearranged

Metastatic Site: pleural fluid, right clavicle lymph node

As of December 2024, Amanda had lived with Stage IV ALK-positive lung cancer for about 2 years and was taking 8 targeted-therapy pills daily.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV Lung Adenocarcinoma With Delayed Pembrolizumab-Related Pneumonitis

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: contralateral lung

After brachytherapy and continued pembrolizumab, imaging 1 year later showed a smaller right hilar lesion with otherwise stable disease. She later recovered from delayed pembrolizumab-related pneumonitis after immunotherapy had been stopped.

PubMed Central
OutcomeStable Disease
Heidi, who was diagnosed with Stage III Lung CancerLung Cancer

Stage III Lung Cancer: Heidi's Survivor Story

Patient Info: Heidi, Female | Stage III

As of November 2024, Heidi was 6 years beyond her Stage IIIA lung cancer diagnosis and active in survivorship and advocacy through The White Ribbon Project; no explicit NED status was provided.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Filipe, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Filipe's Patient Story

Patient Info: Filipe, Male, Under 40 | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, bone, left lung, kidney

As of November 2024, Filipe was living with ongoing Stage IV EGFR exon 19-mutated lung cancer after initial response to osimertinib, later progression and current amivantamab plus chemotherapy.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Stage I lung adenocarcinoma treated with SBRT after pacemaker relocation

Patient Info: Anonymized, Female, 70+ | Stage I

As of December 2024, CT showed complete resolution of the lung ground-glass lesion and no recurrence 4 years and 10 months after SBRT for Stage I lung adenocarcinoma, with stable pacemaker function.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Stage I lung adenocarcinoma: post-lobectomy hemothorax resolved with tPA/DNase

Patient Info: Anonymized, Female, 70+ | Stage I

Early-stage lung adenocarcinoma was surgically treated with left upper lobectomy; postoperative hemothorax resolved after chest-tube drainage, bronchoscopy, and intrapleural tPA/DNase, with no hemothorax recurrence at follow-up.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung Adenocarcinoma With Immune-Related Abdominal Inflammation and Later Bone Progression

Patient Info: Anonymized, male | Stage IV

Biomarkers: PD-L1 30%; KRAS G13X mutation; EGFR/ALK/ROS1 negative

Metastatic Site: bone

After several periods of response or stability, lymph-node progression recurred and bone progression was documented in July 2024. Another treatment line was being planned.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Suspected Stage IIIA NSCLC reclassified as organizing pneumonia and smoking-related inflammation

Patient Info: Anonymized, Female, 70+

Biomarkers: Initial cytology had rare p40-positive cells, but later biopsy favored organizing pneumonia/smoking-related inflammation rather than cancer.

As of November 2024, the suspected lung cancer diagnosis was reclassified as organizing pneumonia/smoking-related inflammation, chemotherapy was avoided, and 3-month surveillance CT showed complete resolution of the previous abnormalities.

PubMed Central
OutcomeCancer-Free / NED
Donnita, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

How I Discovered My LUNG CANCER

Patient Info: Donnita, Female, 60s

As of November 2024, Donnita was sharing her experience as a lung cancer survivor after Stage IA2 non-small cell lung adenocarcinoma found through screening and treated surgically.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage III EGFR exon 19-deleted lung adenocarcinoma: osimertinib and surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion

No sign of metastasis on PET-CT or brain MRI after 24 months of follow-up following neoadjuvant osimertinib, left upper-lobe resection, and adjuvant osimertinib.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage 4 ALK-positive lung cancer: remission on lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: ALK-positive rearrangement; TTF-1-positive

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bone, liver,…

Metastatic ALK-positive lung adenocarcinoma remained in radiologic and clinical remission on lorlatinib after CNS progression on earlier ALK-directed therapy and stereotactic radiosurgery.

PubMed Central
OutcomeLiving With Cancer
Jill, who was diagnosed with Lung CancerLung Cancer

EGFR Lung Cancer: Jill's Survivor Story

Patient Info: Jill Feldman, Female, Under 40

Biomarkers: EGFR-positive

As of November 2024, Jill described living 15 years after her 2009 lung cancer diagnosis; current disease status and whether she remained on treatment were not clearly stated.

The Patient Story
OutcomeSurvivorship / Completed Treatment